A Phase II Randomized, Double-Blind, Placebo-Controlled Trial of Anti-IL17A Therapy for Venous Leg Ulcers

A Phase II randomized, double-blind, placebo-controlled trial investigated the use of anti-IL17A therapy for treating venous leg ulcers, which are associated with significant morbidity and economic burden. The study found that anti-IL17A therapy was well tolerated, did not cause major side effects, and resulted in a 64% average reduction in wound size in ulcers resistant to conventional treatment. However, the authors noted that the small sample size, due to recruitment challenges during the COVID-19 pandemic and narrow eligibility criteria, limits the findings. These promising results suggest that further validation in a Phase III clinical trial is necessary.